Landscape Capital Management L.L.C. Purchases Shares of 7,758 Protagonist Therapeutics, Inc. $PTGX

Key Points

• Landscape Capital Management L.L.C. recently acquired 7,758 shares of Protagonist Therapeutics, Inc., valued at approximately $375,000, indicating growing institutional interest in the company.
• Protagonist Therapeutics' stock price is currently at $59.05, representing an increase of 1.6%, and the company has a market capitalization of $3.67 billion.
• Insider transactions included CEO Dinesh V. Ph D. Patel selling 22,065 shares for over $1.2 million, reflecting a 3.87% decrease in his holdings, which may raise concerns among investors.

Landscape Capital Management L.L.C. purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,758 shares of the company's stock, valued at approximately $375,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PTGX. GF Fund Management CO. LTD. bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $48,000. GAMMA Investing LLC lifted its stake in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after acquiring an additional 728 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Protagonist Therapeutics by 141.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company's stock worth $59,000 after acquiring an additional 710 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Protagonist Therapeutics during the 1st quarter worth approximately $68,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Protagonist Therapeutics by 38.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,992 shares of the company's stock worth $96,000 after acquiring an additional 551 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Stock Performance

PTGX stock traded down $0.74 during trading on Wednesday, reaching $58.11. 993,796 shares of the company traded hands, compared to its average volume of 648,509. Protagonist Therapeutics, Inc. has a 12 month low of $33.31 and a 12 month high of $61.89. The business has a 50 day simple moving average of $54.87 and a 200 day simple moving average of $49.65. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of 83.02 and a beta of 2.22.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The company had revenue of $5.55 million for the quarter, compared to the consensus estimate of $8.32 million. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PTGX. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Citigroup reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a research report on Thursday, August 7th. Finally, JMP Securities lifted their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $67.20.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 22,065 shares of the business's stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $55.05, for a total transaction of $1,214,678.25. Following the transaction, the chief executive officer directly owned 548,538 shares in the company, valued at $30,197,016.90. The trade was a 3.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total value of $237,000.00. Following the transaction, the director owned 9,130 shares in the company, valued at approximately $540,952.50. This trade represents a 30.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 76,859 shares of company stock worth $4,257,877 in the last ninety days. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.